David Geary Selected Research

Neutropenia

1/2017

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Geary Research Topics

Disease

6	Neoplasms (Cancer) 01/2017 - 01/2011
1	Ovarian Neoplasms (Ovarian Cancer) 10/2019
1	Sarcoma (Soft Tissue Sarcoma) 10/2019
1	Breast Neoplasms (Breast Cancer) 10/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2019
1	Transitional Cell Carcinoma 10/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2019
1	Stomatitis 01/2017
1	Vomiting 01/2017
1	Neutropenia 01/2017
1	Fatigue 01/2017
1	Nausea 01/2017
1	Basal Cell Carcinoma (Rodent Ulcer) 06/2013
1	Neuroblastoma 01/2011

Drug/Important Bio-Agent (IBA)

2	PM 01183IBA 01/2017 - 04/2014
1	brivanibIBA 10/2019
1	Transaminases (Aminotransferases)IBA 01/2017
1	CreatinineIBA 01/2017
1	elisidepsinIBA 08/2015
1	Pharmaceutical PreparationsIBA 06/2013
1	HhAntag691IBA 06/2013
1	Sirolimus (Rapamycin)FDA Link 04/2011
1	Sorafenib (BAY 43-9006)FDA Link 04/2011
1	Sunitinib (Sutent)FDA Link 04/2011
1	XK 469 (XK469)IBA 01/2011
1	QuinoxalinesIBA 01/2011

Therapy/Procedure

2	Intravenous Infusions 01/2017 - 08/2015
1	Therapeutics 04/2011